MedTrace Logo

Methylphenidate in Myotonic Dystrophy Type 1

NCT01421992 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2011-08-23

No results posted yet for this study

Summary

The purpose of this study is to determine whether methylphenidate is effective in the treatment of excessive daytime sleepiness due to myotonic dystrophy type 1 (DM1).

Conditions

  • Dystrophia Myotonica 1

Interventions

DRUG

Methylphenidate

One Tablet of methylphenidate, 20 mg per day during 3 weeks

DRUG

Placebo

one tablet placebo per day during 3 weeks

Sponsors & Collaborators

  • Laval University

    lead OTHER

Principal Investigators

  • Jack J Puymirat, MD · University Laval

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2010-08-31
Completion
2010-09-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01421992 on ClinicalTrials.gov